Last reviewed · How we verify
Mycobacterium w immunotherapy — Competitive Intelligence Brief
phase 3
Mycobacterial immunotherapy
Oncology
Biologic
Live · refreshed every 30 min
Target snapshot
Mycobacterium w immunotherapy (Mycobacterium w immunotherapy) — University of Cape Town. Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mycobacterium w immunotherapy TARGET | Mycobacterium w immunotherapy | University of Cape Town | phase 3 | Mycobacterial immunotherapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Mycobacterial immunotherapy class)
- University of Cape Town · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mycobacterium w immunotherapy CI watch — RSS
- Mycobacterium w immunotherapy CI watch — Atom
- Mycobacterium w immunotherapy CI watch — JSON
- Mycobacterium w immunotherapy alone — RSS
- Whole Mycobacterial immunotherapy class — RSS
Cite this brief
Drug Landscape (2026). Mycobacterium w immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/mycobacterium-w-immunotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab